Therapeutic Response

BRAF p.V600E status confers therapeutic sensitivity to Cetuximab in combination with Encorafenib in patients with Colorectal Adenocarcinoma.

Statements

Source and description
Braftovi (encorafenib) [product monograph]. HC. Health Canada approved encorafenib in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.
Braftovi (encorafenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. Encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.
Erbitux (cetuximab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to cetuximab in combination with encorafenib for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.